Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin and Amcasertib in Advanced Solid Tumors
NCT02432326Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Apr 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of napabucasin and amcasertib in solid tumor, sponsored by Sumitomo Pharma America. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Recommended Phase 2 Dose at 20 weeks. Started Apr 2015; status: completed.
02
Drugs
napabucasinamcasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02432326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432326.